BELLEVUE LIFE SCIENCES ACQUISITION CORP.
None
None, None [HQ]
BLACU/Financial Reporting
Income Statements
4 Sheets · Starting from 2020In Million USD. Margins, Growth Rates In %
| Metric | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | |
|
EPS
|
- - | - - | - - | 0.07 | |
| Diluted in mil. | - - | - - | - - | 0.07 | |
|
Profit
|
- - | - - | - - | - - | |
| Gross Margin | - - | - - | - - | - - | |
| Pre Tax | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | |
| ETR | 866.36 | 7,151.03 | 645.65 | 57.25 | |
| Net | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | |
| EBITDA | - - | - - | - - | -1.00 | |
| EBITDA Margin | - - | - - | - - | - - | |
| Operating Income | - - | - - | - - | -1.00 | |
| Operating Margin | - - | - - | - - | - - | |
| Interest Income | - - | - - | - - | - - | |
| Loss | - - | - - | - - | -1.00 | |
| Cost of Revenue | - - | - - | - - | - - | |
|
Operating Expenses
|
- - | - - | - - | -1.00 | |
| R&D | - - | - - | - - | - - | |
| G&A | - - | - - | - - | -1.00 | |
| SG&A | - - | - - | - - | -1.00 | |
| S&M | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | |
| Interest Expenses | - - | - - | - - | - - | |
| Other Expenses | - - | - - | - - | -2.00 | |
|
WA Shares Outstanding
|
7.00 | 7.00 | 9.00 | 5.00 | |
| Diluted | 7.00 | 7.00 | 9.00 | 5.00 |